Seagen to Showcase Data from Growing Oncology Portfolio During Virtual Scientific Program of the 2021 ASCO Annual Meeting
Seagen Inc. (Nasdaq:SGEN) today announced the presentation of new data from its growing pipeline of marketed and investigational therapies at the virtual scientific program of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 4-8.
“Emerging data and the breadth of our clinical development programs continue to illustrate progress across our oncology portfolio, highlighting the company’s research efforts in multiple cancers with a high unmet need,” said Roger Dansey, M.D., Chief Medical Officer at Seagen. “Notably, we are looking forward to sharing updated results of the EV-103 and EV-201 clinical trials for PADCEV® (enfortumab vedotin-ejfv) in locally advanced or metastatic urothelial cancer and additional data from the HER2CLIMB trial of TUKYSA® (tucatinib) in previously treated HER2+ metastatic breast cancer patients.”
Key data to be presented include:
Abstract Title |
Abstract # |
Presentation type |
Lead Author |
PADCEV® (enfortumab vedotin-ejfv) |
|||
Study EV-103: Update on durability results and long-term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC) |
4528 |
Poster Presentation |
T. Friedlander |
Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors: An updated analysis of EV-201 Cohort 2 |
4524 |
Poster Presentation |
B. McGregor |
Quality of life, functioning, and symptoms in patients with previously treated locally advanced or metastatic urothelial carcinoma from EV-301: A randomized Phase 3 trial of enfortumab vedotin vs chemotherapy |
4539 |
Poster Presentation |
R. Mamtani |
KEYNOTE-B15/EV-304: Randomized Phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC) |
TPS4587 |
Poster Presentation |
C. Hoimes |
